These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36765872)

  • 1. Immune Checkpoint Receptor/Ligand Expression and Chemotherapy in Colorectal Cancer.
    Benelli R; Zocchi MR; Poggi A
    Cancers (Basel); 2023 Feb; 15(3):. PubMed ID: 36765872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of Curcumin on multi-level immune checkpoint blockade and T cell dysfunction in head and neck cancer.
    Liu L; Lim MA; Jung SN; Oh C; Won HR; Jin YL; Piao Y; Kim HJ; Chang JW; Koo BS
    Phytomedicine; 2021 Nov; 92():153758. PubMed ID: 34592487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic Silencing of Immune-Checkpoint Receptors in Bone Marrow- Infiltrating T Cells in Acute Myeloid Leukemia.
    Radpour R; Stucki M; Riether C; Ochsenbein AF
    Front Oncol; 2021; 11():663406. PubMed ID: 34017684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defining the Immune Checkpoint Landscape in Human Colorectal Cancer Highlights the Relevance of the TIGIT/CD155 Axis for Optimizing Immunotherapy.
    Ducoin K; Bilonda-Mutala L; Deleine C; Oger R; Duchalais E; Jouand N; Bossard C; Jarry A; Gervois-Segain N
    Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of cytotoxic effector cells towards cholangiocellular, pancreatic, and colorectal tumor cells by activation of the immune checkpoint CD40/CD40L on dendritic cells.
    Sadeghlar F; Vogt A; Mohr RU; Mahn R; van Beekum K; Kornek M; Weismüller TJ; Branchi V; Matthaei H; Toma M; Schmidt-Wolf IGH; Kalff JC; Strassburg CP; González-Carmona MA
    Cancer Immunol Immunother; 2021 May; 70(5):1451-1464. PubMed ID: 33180184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma.
    Raphael I; Kumar R; McCarl LH; Shoger K; Wang L; Sandlesh P; Sneiderman CT; Allen J; Zhai S; Campagna ML; Foster A; Bruno TC; Agnihotri S; Hu B; Castro BA; Lieberman FS; Broniscer A; Diaz AA; Amankulor NM; Rajasundaram D; Pollack IF; Kohanbash G
    Front Immunol; 2021; 12():637146. PubMed ID: 34025646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
    Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
    Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing the expression of programmed death ligand 2 (PD-L2) but not 4-1BB ligand in colorectal cancer cells.
    Shakerin P; Sedighi Moghadam B; Baghaei K; Safaei Naraghi Z; Kamyab Hesari K; Asadzadeh Aghdaei H; Shokouhi Shoormasti R; Fazeli MS; Nourizadeh M
    Mol Biol Rep; 2020 Aug; 47(8):5689-5697. PubMed ID: 32661872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Expression of Immune Checkpoint Receptors and Ligands in the Colorectal Cancer Tumor Microenvironment.
    Neupane P; Mimura K; Nakajima S; Okayama H; Ito M; Thar Min AK; Saito K; Onozawa H; Fujita S; Sakamoto W; Saito M; Saze Z; Momma T; Kono K
    Anticancer Res; 2021 Oct; 41(10):4895-4905. PubMed ID: 34593437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid, sensitive and cost-effective determination of immune checkpoint inhibitor activity using a magnetic bead-based binding assay.
    Meng Q; Fu Y; Li S; Yan Y; Duan D; Anthony DD; Zhu Y; Wu X; Qian F; Wu C
    J Immunol Methods; 2021 Nov; 498():113134. PubMed ID: 34464606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinant roles of dendritic cell-expressed Notch Delta-like and Jagged ligands on anti-tumor T cell immunity.
    Tchekneva EE; Goruganthu MUL; Uzhachenko RV; Thomas PL; Antonucci A; Chekneva I; Koenig M; Piao L; Akhter A; de Aquino MTP; Ranganathan P; Long N; Magliery T; Valujskikh A; Evans JV; Arasada RR; Massion PP; Carbone DP; Shanker A; Dikov MM
    J Immunother Cancer; 2019 Apr; 7(1):95. PubMed ID: 30940183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules.
    Zhou G; Sprengers D; Mancham S; Erkens R; Boor PPC; van Beek AA; Doukas M; Noordam L; Campos Carrascosa L; de Ruiter V; van Leeuwen RWF; Polak WG; de Jonge J; Groot Koerkamp B; van Rosmalen B; van Gulik TM; Verheij J; IJzermans JNM; Bruno MJ; Kwekkeboom J
    J Hepatol; 2019 Oct; 71(4):753-762. PubMed ID: 31195061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulation of Interferon-
    Lv C; Yuan D; Cao Y
    J Pharmacol Exp Ther; 2021 Jan; 376(1):21-28. PubMed ID: 33158943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment of a mechanism-based in vitro coculture assay for evaluating the efficacy of immune checkpoint inhibitors.
    Kim MJ; Hong KH; Lee BR; Ha SJ
    Cancer Immunol Immunother; 2022 Nov; 71(11):2777-2789. PubMed ID: 35437609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer.
    Fathi M; Pustokhina I; Kuznetsov SV; Khayrullin M; Hojjat-Farsangi M; Karpisheh V; Jalili A; Jadidi-Niaragh F
    IUBMB Life; 2021 May; 73(5):726-738. PubMed ID: 33686787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depleting Tumor Cells Expressing Immune Checkpoint Ligands-A New Approach to Combat Cancer.
    Marcucci F; Rumio C
    Cells; 2021 Apr; 10(4):. PubMed ID: 33921301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive analysis of inhibitory checkpoint ligand expression by glioblastoma cells.
    Robilliard LD; Yu J; Anchan A; Joseph W; Finlay G; Angel CE; Scott Graham E
    Immunol Cell Biol; 2021 Apr; 99(4):403-418. PubMed ID: 33217047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Complement Receptors C3aR and C5aR Are a New Class of Immune Checkpoint Receptor in Cancer Immunotherapy.
    Wang Y; Zhang H; He YW
    Front Immunol; 2019; 10():1574. PubMed ID: 31379815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of immune checkpoint inhibitors in colorectal cancer: a systematic review and meta-analysis.
    Zeng T; Fang X; Lu J; Zhong Y; Lin X; Lin Z; Wang N; Jiang J; Lin S
    Int J Colorectal Dis; 2022 Jan; 37(1):251-258. PubMed ID: 34716473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Checkpoint and Other Receptor-Ligand Pairs Modulating Macrophages in Cancer: Present and Prospects.
    Yang Y; Zhang W; Lan P
    Cancers (Basel); 2022 Dec; 14(23):. PubMed ID: 36497444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.